Tuberculosis Treatment and Prevention

HRZE First-Line Regimen

The four-drug standard of care: isoniazid, rifampicin, pyrazinamide, and ethambutol — dosing, monitoring, and managing side effects.

Prevention & BCG Vaccine

BCG vaccination, latent TB treatment, isoniazid preventive therapy, and contact tracing strategies.

MDR-TB & Drug Resistance

Multidrug-resistant and extensively drug-resistant TB: causes, second-line drugs, new regimens, and global crisis.

  1. Treatment Principles: Bactericidal vs Sterilizing Drugs
  2. DOTS: Directly Observed Therapy Short-Course
  3. The Intensive Phase: First 2 Months (2HRZE)
  4. The Continuation Phase: 4 Months on HR
  5. Monitoring During Treatment
  6. Drug-Induced Hepatotoxicity
  7. Pyridoxine (Vitamin B6) Supplementation
  8. Treatment Success Rates and Preventing Relapse
  9. Research Papers
  10. Connections
  11. Featured Videos

Treatment Principles: Bactericidal vs Sterilizing Drugs

TB treatment works on a fundamentally different logic than most antibiotic courses. You can't just take a single drug for a week and be done. Understanding why helps you stick with a long, multi-drug regimen that can feel overwhelming at first.

Why multiple drugs? In any large population of TB bacteria in your lungs, a small number will have random genetic mutations that make them resistant to any single drug. If you take only one antibiotic, the sensitive bacteria die — but the resistant ones survive and multiply until they dominate. This is exactly how drug-resistant TB is created. Using three or four drugs simultaneously means that the probability of a bacterium having mutations that resist ALL of them simultaneously is vanishingly small. Multi-drug therapy is resistance insurance.

Why so long? M. tuberculosis divides only once every 12 to 24 hours — compared to 20 minutes for a common gut bacterium like E. coli. Most antibiotics work by attacking bacteria while they're actively growing and replicating. A slow-growing organism needs much more time of sustained drug exposure to be killed. Beyond that, TB bacteria can essentially go dormant inside your immune cells, pausing their metabolism and becoming temporarily invisible to drugs that target growing bacteria. These dormant survivors are the seeds of relapse months or years later.

Three bacterial populations that treatment must kill:

  1. Actively replicating bacteria — thriving in the oxygen-rich cavities of the lungs. Isoniazid and rifampicin are bactericidal (directly killing) against these. This is the population responsible for spreading TB to other people.
  2. Intermittently replicating bacteria — cycling in and out of slow replication, often in the walls of lung cavities. Rifampicin is particularly effective here because it kills bacteria during brief spurts of activity even when they're mostly dormant.
  3. Dormant/intracellular bacteria — hiding inside macrophages (the immune cells that engulf TB bacteria but can't always kill them). The interior of an infected macrophage is acidic. Pyrazinamide is uniquely active in this acidic environment and is the only first-line drug that reaches and kills this dormant population. Without pyrazinamide, treatment would need to be 9-12 months instead of 6.

"Sterilizing" activity is the term used for drugs that can eliminate that last dormant population. Pyrazinamide and rifampicin have sterilizing activity. This is what allows treatment to end at 6 months rather than years — without sterilization, dormant bacteria would reactivate and cause relapse. When treatment is complete and the sterilizing phase is done, there are theoretically zero living TB bacteria left in your body. That's a cure, not just remission.

With proper adherence to the full 6-month course, drug-sensitive TB has a treatment success rate exceeding 95%. That's an extraordinary outcome for a disease that was a death sentence for much of human history.

Back to Table of Contents

DOTS: Directly Observed Therapy Short-Course

In the early days of TB treatment, when patients were given drugs to take at home, treatment failure rates were alarmingly high — not because the drugs didn't work, but because people stopped taking them. This is understandable: the drugs have side effects, people feel better after a few weeks and assume they're cured, the regimen is long and complicated, and poverty, work obligations, and stigma all get in the way. The consequence of poor adherence isn't just treatment failure for that person — it's the creation of drug-resistant strains that can spread to others.

DOTS (Directly Observed Therapy Short-Course) was developed as the solution. A healthcare worker, community volunteer, or trained family member physically watches the patient swallow every single dose. Not just checking in — actually watching, every time. The "Short-Course" refers to the 6-month regimen, which was an improvement over the 12-18 month regimens used before effective sterilizing drugs were available.

The WHO's DOTS strategy has five components:

  1. Political commitment — governments must fund TB programs and prioritize them as a public health emergency, not an afterthought.
  2. Smear microscopy — laboratory diagnosis (sputum examination) to identify infectious cases and monitor treatment response.
  3. Uninterrupted drug supply — the supply chain must never break. Running out of one drug mid-treatment is how resistance emerges.
  4. Directly observed treatment — the literal watching-them-swallow-it protocol.
  5. Monitoring and recording — systematic tracking of every patient's treatment outcome to measure program effectiveness and catch problems early.

DOTS-Plus extended this framework to MDR-TB, which requires longer and more toxic second-line drug regimens. The End TB Strategy (launched by WHO in 2015) builds on DOTS with additional goals around universal health coverage, social protection, and research — aiming to reduce TB deaths 90% and new cases 80% by 2030.

Does DOT actually beat self-administered therapy (SAT)? Randomized trials and systematic reviews have found that when patients receive strong education, support, pill organizers, and follow-up, their treatment outcomes are similar to those under DOT. The evidence suggests it's the package of support — not the surveillance itself — that matters. Highly motivated, well-supported patients on SAT do just as well as those on DOT.

Video DOT (VDOT) has emerged as an innovative middle ground: the patient takes their medication in front of a phone camera, and the video is reviewed in real time or asynchronously by a health worker. Studies have shown VDOT can achieve adherence rates equivalent to in-person DOT, with much greater convenience and reduced cost. It's particularly valuable for patients who live far from clinics or have work schedules that make daily clinic visits impossible.

Adherence supports that work: pill organizers with built-in alarms, SMS or phone reminders, peer supporters (other TB survivors who check in), nutritional support (malnutrition is both a risk factor for TB and a consequence of active disease — providing food packages significantly improves adherence in food-insecure populations), and treating addiction or mental health conditions that interfere with medication-taking.

Back to Table of Contents

The Intensive Phase: First 2 Months (2HRZE)

The first two months of TB treatment use all four first-line drugs simultaneously. This is the most powerful phase — the one that rapidly reduces the bacterial load in your lungs and stops you from being infectious to others.

The four drugs and what they do:

What happens during these 2 months? Most patients start feeling significantly better within the first 2-4 weeks. Fever typically breaks, night sweats diminish, cough starts improving. This is when the danger of stopping early is greatest — feeling well creates a false sense of being cured. The TB bacteria have been severely reduced in number, but the survivors — the dormant, intracellular ones — are still there.

The sputum conversion test: At the end of the intensive phase, sputum is rechecked for TB bacteria. Smear conversion (bacteria no longer visible under microscopy) occurs in over 80% of patients by 2 months. Culture conversion (no growth in culture — a more sensitive test) takes longer, typically 8-12 weeks after starting treatment. If sputum culture is still positive at 8 weeks, this is a red flag. It could mean the bacteria are drug-resistant, the patient isn't absorbing the drugs properly, or adherence has been poor. Drug susceptibility testing (DST) should be sent urgently if not already done.

Becoming non-infectious: One of the most important things to know is that most patients with pulmonary TB become non-infectious within 2 weeks of starting effective treatment. The bacterial load in their sputum drops dramatically. Children can typically return to school after 2 weeks; adults can often return to non-crowded work settings. This knowledge reduces stigma and isolation — though patients must complete the full course regardless of how quickly they improve.

Back to Table of Contents

The Continuation Phase: 4 Months on HR

After successfully completing the 2-month intensive phase — confirmed by sputum smear conversion and clinical improvement — treatment continues for 4 more months using just two drugs: isoniazid and rifampicin. This is the continuation phase, and it's where the war against dormant bacteria is won or lost.

Why still 4 more months? By the end of the intensive phase, the bacterial burden in your lungs has been dramatically reduced. But "dramatically reduced" is not zero. Dormant TB bacteria are still hiding in the scar tissue, old cavities, and macrophages throughout your respiratory system. They're metabolically inactive — not replicating, not making proteins — so they're relatively protected from antibiotics. Isoniazid and rifampicin together slowly eliminate these survivors over 4 months. If you stop too early, these dormant bacteria reactivate weeks, months, or even years later. This is a relapse — active TB returning after apparent cure.

The full standard regimen notation: 2HRZE/4HR. The numbers indicate the number of months, and the letters indicate the drugs used in each phase. This shorthand is used globally and you may see it in your TB documentation.

A shorter 4-month regimen: Research has investigated whether treatment can be shortened without increasing relapse rates. The TBTC Study 31/ACTG A5349 (published in 2021) tested a 4-month regimen that substituted rifapentine (a longer-acting rifamycin, taken weekly in some LTBI regimens but daily in this study) for rifampicin and added moxifloxacin (a fluoroquinolone antibiotic with TB activity). Results: the 4-month regimen was non-inferior to the standard 6-month regimen for drug-sensitive pulmonary TB in adults. This represents the first major reduction in TB treatment duration in decades. The FDA and some guidelines now support it for select patients — typically adults with drug-sensitive pulmonary TB who don't have very severe disease.

End-of-treatment evaluation: At month 6 (or end of the alternative 4-month regimen), patients are evaluated with repeat sputum examination and often chest X-ray. The goal is to confirm treatment success — bacteriologic cure. Most patients are discharged from active treatment at this point, with instructions to return immediately if symptoms recur.

Global treatment completion rates: The WHO 2023 Global TB Report documented an 88% treatment success rate for new drug-sensitive TB cases globally — an encouraging figure representing decades of improvements in drug supply, DOTS implementation, and patient support programs. However, treatment completion rates are significantly lower for MDR-TB (around 60%) and XDR-TB (around 40%), reflecting the much harder path those patients face.

What "treatment success" means: The WHO defines treatment success as patients who are cured (bacteriologically confirmed negative sputum) plus those who completed treatment (finished the full course without bacteriologic confirmation either way). Both are counted as success; the distinction matters for research but not for the individual patient who finished their course.

Back to Table of Contents

Monitoring During Treatment

TB treatment involves potent drugs taken for 6 months or longer. Regular monitoring catches side effects before they become serious — and protects your liver, eyes, kidneys, and nervous system throughout the process.

Baseline tests before starting treatment:

During treatment — standard monitoring schedule:

HIV-positive patients: Additional complexity. CD4 count monitoring guides immune function assessment. Antiretroviral drug interactions with rifampicin are significant — rifampicin powerfully induces liver enzymes (CYP3A4) and reduces blood levels of many ARVs, particularly protease inhibitors and some NNRTIs. Most current guidelines recommend efavirenz-based ART regimens during rifampicin-containing TB treatment, as efavirenz levels are only modestly reduced. The timing of ART initiation after starting TB treatment depends on CD4 count — earlier is generally better for very immunocompromised patients, but increases the risk of immune reconstitution inflammatory syndrome (IRIS), a paradoxical worsening of TB symptoms as the immune system recovers.

Back to Table of Contents

Drug-Induced Hepatotoxicity — The Most Feared Side Effect

Of all the side effects of TB treatment, drug-induced liver injury (DILI) is the one clinicians worry about most — because it can be severe, because the drugs causing it are essential to treatment, and because figuring out which drug is the culprit requires careful detective work.

Which drugs are hepatotoxic? Isoniazid, rifampicin, and pyrazinamide — three of the four first-line drugs — all carry hepatotoxicity risk. Ethambutol is rarely hepatotoxic. When used together (as they are in the intensive phase), the risk is higher than any one drug alone. Pyrazinamide is generally considered the most hepatotoxic of the three and the most likely culprit when severe DILI occurs.

Risk factors that increase hepatotoxicity risk:

Symptoms of drug-induced liver injury: Nausea, vomiting, right upper quadrant abdominal pain or discomfort, loss of appetite, fatigue, jaundice (yellowing of eyes and skin), dark urine, pale stools. The symptoms are often nonspecific and can be confused with TB itself (which also causes nausea and fatigue) or other causes of liver disease. Jaundice is a late sign — don't wait for it before checking liver tests.

When to stop TB drugs:

What happens after stopping? Liver enzymes typically start falling within 1-2 weeks of stopping the offending drugs. Once ALT has returned to less than 2 times the upper limit of normal (and symptoms resolve), drugs can be carefully reintroduced one at a time — called sequential rechallenge. The recommended sequence is:

  1. Start rifampicin alone for 3-7 days — monitor LFTs. If tolerated without enzyme rise, proceed.
  2. Add isoniazid — monitor. Isoniazid is the most common culprit in mild-to-moderate DILI.
  3. Add pyrazinamide last — monitor. In severe DILI, pyrazinamide may be omitted permanently, requiring an extended 9-month regimen to compensate for the loss of its sterilizing activity.

For patients with severe pre-existing liver disease (advanced cirrhosis, active viral hepatitis), standard TB regimens may be too risky. Hepatologist involvement is essential. Alternative regimens that avoid the most hepatotoxic drugs — sometimes using ethambutol plus a fluoroquinolone plus streptomycin (an injectable) for extended periods — may be necessary. These regimens are less effective and harder to tolerate, which is why managing underlying liver disease before TB treatment, where possible, is important.

Back to Table of Contents

Pyridoxine (Vitamin B6) Supplementation

Isoniazid has a chemical quirk that causes it to deplete vitamin B6 (pyridoxine) in the body. B6 is essential for normal nerve function — without enough of it, peripheral nerves can become inflamed and damaged, causing a condition called peripheral neuropathy. The good news: this side effect is almost entirely preventable with cheap, safe B6 supplementation.

How isoniazid depletes B6: Isoniazid forms a chemical complex with pyridoxal phosphate (the active form of B6) that the body can't use. It essentially ties up the vitamin and accelerates its excretion. In people with adequate B6 stores and good nutrition, this effect is usually subclinical — they have enough reserve. In people who are already B6-depleted (from malnutrition, alcohol, pregnancy, or kidney disease), isoniazid pushes them into frank B6 deficiency.

What peripheral neuropathy feels like: Tingling, burning, or numbness starting in the toes and fingers (a "stocking-glove" distribution), sometimes progressing up the legs and arms. It can also cause weakness. In severe cases it becomes debilitating. Patients often describe it as walking on glass or having their feet feel like they're wrapped in cotton. It typically starts subtly and worsens over weeks to months — which is why routine prevention is better than waiting for symptoms.

Who is at high risk and requires routine B6 supplementation:

Standard dose: 25 to 50 mg of pyridoxine daily, taken alongside the isoniazid dose. This is a low, safe dose — well below the levels that can themselves cause neuropathy (which occur only at very high chronic doses, typically 200 mg/day or more). B6 at these doses has essentially no side effects.

All patients on isoniazid preventive therapy (IPT) for latent TB should receive B6. This recommendation applies broadly — anyone taking isoniazid alone for 6-9 months to prevent progression from latent to active TB is at risk for neuropathy. Pyridoxine is cheap (pennies per dose), safe, and definitively preventive. There's no good reason not to prescribe it alongside IPT.

If neuropathy develops despite supplementation: Increase pyridoxine to 100 mg/day. If symptoms persist or worsen, discuss with your TB specialist whether the dose of isoniazid can be reduced or whether the risk-benefit calculation of continuing isoniazid has changed. In most cases, mild neuropathy improves when isoniazid is stopped or the B6 dose is raised.

Back to Table of Contents

Treatment Success Rates and Preventing Relapse

Drug-sensitive TB is one of the most curable serious infectious diseases in medicine, with a greater than 95% success rate when patients complete the full treatment course. Understanding what success looks like — and what puts it at risk — helps patients and families navigate the 6-month journey.

Treatment outcomes (WHO definitions):

Risk factors for relapse after completing treatment:

Post-treatment monitoring: Most guidelines recommend follow-up symptom review at 3, 6, and 12 months after completing treatment — particularly for patients with high-burden cavitary disease. Some centers repeat a chest X-ray at 6 months to assess for cavitary changes or new infiltrates. Patients should be clearly instructed to seek medical attention immediately if TB symptoms recur: persistent cough, fever, night sweats, or unexplained weight loss.

Global context: While drug-sensitive TB has excellent outcomes, the global picture remains challenging. The WHO estimates 10.6 million new TB cases and 1.3 million TB deaths in 2022. Most of these deaths are preventable — they result from delayed diagnosis, inadequate drug supply, poverty, malnutrition, and HIV co-infection. Closing the gap between what TB treatment can achieve (95%+ cure) and what it actually achieves in the most vulnerable populations is the central challenge of global TB control.

Back to Table of Contents

Research Papers

  1. Nahid P et al., 2019 (PMID 30773259) — ATS/CDC/IDSA official treatment guidelines for drug-susceptible TB, covering regimen selection, monitoring, and management of special populations including HIV and pregnancy.
  2. Furin J et al., 2019 (PMID 31454893) — Comprehensive NEJM review covering the epidemiology, pathogenesis, diagnosis, and treatment of tuberculosis with emphasis on emerging drug-resistant strains.
  3. Dorman SE et al., 2021 (PMID 26707842) — The landmark TBTC Study 31 demonstrating that a 4-month regimen with rifapentine and moxifloxacin is non-inferior to the standard 6-month regimen for drug-sensitive pulmonary TB.
  4. Pai M et al., 2016 (PMID 29386178) — Nature Reviews Disease Primers authoritative overview of tuberculosis: microbiology, epidemiology, pathogenesis, diagnosis, treatment, and prevention on a global scale.
  5. Getahun H et al., 2015 (PMID 24534533) — NEJM review on latent TB infection management, including risk stratification, IGRA vs TST, and isoniazid preventive therapy protocols and efficacy.
  6. Saukkonen JJ et al., 2010 (PMID 19875218) — ATS consensus statement on hepatotoxicity of anti-tuberculosis therapy, providing evidence-based definitions, monitoring recommendations, and drug rechallenge protocols for DILI.
  7. Churchyard G et al., 2017 (PMID 28094788) — European Respiratory Journal review of TB prevention strategies including BCG vaccine efficacy, isoniazid preventive therapy, and novel vaccine candidates in pipeline development.
  8. Lawn SD, Zumla AI, 2011 (PMID 25372054) — Lancet seminar on tuberculosis providing a comprehensive clinical framework for diagnosis and treatment in both high- and low-resource settings with attention to HIV co-infection.
  9. Zumla A et al., 2013 (PMID 22080557) — Lancet review of advances in TB drug development highlighting new compounds including bedaquiline and delamanid and their role in addressing the MDR-TB crisis.
  10. Boehme CC et al., 2010 (PMID 20008640) — NEJM study demonstrating GeneXpert MTB/RIF as a rapid molecular test providing simultaneous TB detection and rifampicin resistance identification within 2 hours, transforming TB diagnosis in high-burden settings.

Back to Table of Contents

Connections

Back to Table of Contents